Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10276-060002	Application No.	
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant George King		
		Filing Date	Group Art Unit / 6 3 5	

	U.S. Patent Documents						
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
92	AA	5,674,862	10/07/97	Heath et al.			
00	AB						
	AC						
	AD						

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Trans Yes	slation No
	AE							
	AF							
	AG			·				
	AH							

(Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner	Desig.	Document
Initial	, AI	Jirousek et al. J. Med. Chem. 1996, Vol. 39, pp 2664-2671.
00	AJ	Kubocki et al. Circulation, Feb., 2000, Vol. 101 (6), pp 676-681.
	AK	Jack et al. Deabetes, May, 1999, Vol. 48 (5), SA 130.
	AL	Tamm et al. The Lancet, 2001, Vol. 358, pp 489-497.
	AM	Agrawal et al. Molecular Med., 2000, Vol. 6, pp 72-81.
	AN	Crooke, S. Antisense Res. and Applica., 1998, Chapter 1, pp I-50. Springer-Verlag, Pub.
	AO	Chirila et al. Biomaterials, 2002, Vol. 23, pp 321-342.
	AP	Branch, A., TIBS., 1998, Vol. 23, pp 45-50
	AQ	Ha et al., "Inhibition of Protein Kinase C (PKC) Normalized", 1999, Diabetes, Vol.48, No.SUPPL.1; A270, Abstract
	AR	Hink et al., "Mechanisms Underlying Endothelial", 2001, Circ.Res., Vol.88; 251, Abstract
	AS	Baron AD, Brechtel-Hook C, Johnson A, Cronin J, Learning R, Steinberg HO. Effect of perfusion rate on the time course of insulin mediated skeletal muscle glucose uptake. <i>Am J Physiol</i> . 1996;271:E1067-E10724
	AT	Becker TC, Noel RJ, Coats WS, Gomez-Foix, Alam T, Gerard RD, Newgard CB. Use of recombinant adenovirus for metabolic engineering of mammalian cells. <i>Methods Cell Biol</i> . 1994;43:161-189
Evoninas Cias		2 Date Considered

Examiner Signature \	Date Considered
72-	5-26-06
EXAMINER: Initials citation considered. Draw line through citation if no	t in conformance and not considered. Include copy of this form with
next communication to applicant.	
	Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attomey's Docket No. 10276-060002	Application No.	
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant George King		
		Filing Date	Group Art Unit	

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner	Desig.	Decument
Initial	ID AU	Document Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254
00	AV	Bredt DS, Hwang PM, Snyder SH. Localization of nitric oxide synthase indicating a neural role for nitric oxide. <i>Nature</i> . 1990;347:768-770
	AW	Cheatham B, Vlahos CJ, Cheatham L, Wang L, Blenis J, Kahn CR. Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. <i>Mol Cell Biol.</i> 1994;14:4902-4911
	AX	Feener EP, King GL. Vascular dysfunction in diabetes mellitus. Lancet. 1997;350(suppl 1):SI9-SI13
	AY	Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC \(\mathbb{G} \) inhibitor. Science. 1996;272:728-731
	AZ	Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47:859-866
	AAA	Lyons CR, Orloff GJ, Cunningham JM. Molecular cloning and functional expression of an inducible nitric oxide synthase from a murine macrophage cell line. <i>J Biol Chem.</i> 1992;267:6370-6374
	ABB	O'Brien RM, Granner DK. Regulation of gene expression by insulin. <i>Physiol Rev.</i> 1996;76:1109-1161
	ACC	Ohara et al., Regulation of Endothelial Constitutive Nitric Oxide Synthase by Protein Kinase C. Hypertension, 1995; 25: 415-420
	ADD	Okada T, Sakuma L, Fukui Y, Hazeki O, Ui M. Blockage of chemotactic peptide induced stimulation if neutrophils by wortmannin as a result of selective inhibition of phosphatidylinositol 3-kinase. J Biol Chem. 1994;269:3563-3567
	AEE	Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. <i>J Clin Invest.</i> 1994;94:1172-1179
	AFF	Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perret T, Jakanes M, Baudet V, Boissin P, Boursier E, Loriolle F. The bisindolylmaleimide GF109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem. 1991;266:15771-15781
	AGG	Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. <i>Kidney Int.</i> 1994;45:598-604
	АНН	Utriainen T, Makimattila S, Virkamaki A, Bergholm R, Yki-Jarvinen H. Dissociation between insulin sensitivity of glucose uptake and endothelial function in normal subjects. <i>Diabetologia</i> . 1996;39:1477-1482
	AII	Yki-Jarvinen H, Utriainen T. Insulin-induced vasodilation: physiology or pharmacology? Diabetologia. 1998;41:369-379
	AJJ	Yoshizumi M, Perrella MA, Burnett JC Jr, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half. Circ Res. 1993;73:205-209

Examiner Signature 3	Date Considered 5-26-06
EXAMINER: Initials citation considered, thraw line through citation if no next communication to applicant.	t in conformance and not considered. Include copy of this form with
	Substitute Disclosure Form (PTO-1449)

Sheet	3	of	3

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10276-060002	Application No.	
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant George King		
		Filing Date	Group Art Unit	
(37 CFR §1.98(b))				

	Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document	
92/	AKK	Young ME, Leighton B. Evidence for altered sensitivity of the nitric oxide/cGMP-signaling cascade in insulin-resistant skeletal muscle. <i>Biochem J.</i> 1998;329:73-79	

Examiner Signature Date Considered EXAMINER: Initials citation considered Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.